Base de dados : MEDLINE Pesquisa : C04.557.337.428.100 [Categoria DeCS] Referências encontradas : 263 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 27

ir para página

1 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 29072953 [Au] Autor: Charles NJ; Boyer DF [Ad] Endereço: From the Department of Pathology, The University of Michigan, Ann Arbor. [Ti] Título: Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls. [So] Source: Arch Pathol Lab Med;141(11):1462-1468, 2017 Nov. [Is] ISSN: 1543-2165 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Mixed-phenotype acute leukemia (MPAL) is a heterogeneous category in the World Health Organization classification that comprises acute leukemias with discrete admixed populations of myeloid and lymphoid blasts ("bilineal") or with extensive coexpression of lymphoid and myeloid markers in a single blast population ("biphenotypic"). Flow cytometric findings suggestive of MPAL are often met with consternation by pathologists and oncologists alike, owing to unfamiliarity with the disease and uncertainty about how MPAL fits into established paradigms for treatment of acute leukemia. The purpose of this review is to explain the diagnostic criteria for MPAL, summarize its biological and clinical features, and address common diagnostic pitfalls of these unusual leukemias. [Mh] Termos MeSH primário: Leucemia Aguda Bifenotípica/diagnóstico Guias de Prática Clínica como Assunto [Mh] Termos MeSH secundário: Biomarcadores Tumorais/sangue Biomarcadores Tumorais/metabolismo Diagnóstico Diferencial Proteínas de Fusão bcr-abl/sangue Proteínas de Fusão bcr-abl/genética Proteínas de Fusão bcr-abl/metabolismo Histona-Lisina N-Metiltransferase/sangue Histona-Lisina N-Metiltransferase/genética Histona-Lisina N-Metiltransferase/metabolismo Seres Humanos Imuno-Histoquímica/tendências Imunofenotipagem/tendências Leucemia Aguda Bifenotípica/genética Leucemia Aguda Bifenotípica/metabolismo Leucemia Aguda Bifenotípica/terapia Proteína de Leucina Linfoide-Mieloide/sangue Proteína de Leucina Linfoide-Mieloide/genética Proteína de Leucina Linfoide-Mieloide/metabolismo Prognóstico Translocação Genética Organização Mundial da Saúde [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (BCR-ABL1 fusion protein, human); 0 (Biomarkers, Tumor); 0 (MLL protein, human); 149025-06-9 (Myeloid-Lymphoid Leukemia Protein); EC 2.1.1.43 (Histone-Lysine N-Methyltransferase); EC 2.7.10.2 (Fusion Proteins, bcr-abl) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171106 [Lr] Data última revisão: 171106 [Sb] Subgrupo de revista: AIM; IM [Da] Data de entrada para processamento: 171027 [St] Status: MEDLINE [do] DOI: 10.5858/arpa.2017-0218-RA

2 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28527401 [Au] Autor: Tan J; Wang Y; Yu SJ; Ma YY; Lei HY; Liu QF [Ad] Endereço: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China; Department of Hematology, Jingzhou First People's Hospital, Yangtze University, Jingzhou, Hubei, China. [Ti] Título: Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia. [So] Source: Leuk Res;59:1-7, 2017 Aug. [Is] ISSN: 1873-5835 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: The cure of acute leukemia by allogeneic hematopoietic stem cell transplantation (allo-HSCT) is closely linked to major complications leading to adverse outcomes, including graft-versus-host disease (GVHD), disease relapse and death. This study retrospectively investigated a consecutive series of 312 adult patients with acute leukemia receiving allo-HSCT by using a novel concept of GVHD-free/relapse-free survival (GRFS), and further evaluated the impact of clinical factors on GRFS. Results indicated that the 1- and 2-year GRFS were 54.8% and 51.5%, respectively. In multivariable analysis, recipient age >35years (HR 1.676; p=0.006), diagnosis of acute lymphoblastic leukemia (HR 1.653; p=0.027) and acute biphenotypic leukemia (HR 2.175; p=0.010), advanced disease (HR 2.702; p<0.001), and donor age >35 years (HR 1.622; p=0.008) were significantly associated with inferior GRFS post-HSCT. GRFS of haploidentical-related donor transplant was comparable to that of matched sibling donor or matched unrelated donor transplant. Furthermore, prophylactic donor lymphocyte infusion (DLI) had an overall beneficial effect on GRFS (HR 0.645, p=0.044). Collectively, with a better understanding of these significant prognostic factors which impacted on GRFS, we can effectively evaluate the risk and probability of real recovery after allo-HSCT, further optimizing the therapeutic avenues for acute leukemia. [Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/mortalidade Transplante de Células-Tronco Hematopoéticas/efeitos adversos Leucemia/diagnóstico Prognóstico [Mh] Termos MeSH secundário: Doença Aguda Adolescente Adulto Fatores Etários Aloenxertos Doadores de Sangue Intervalo Livre de Doença Feminino Doença Enxerto-Hospedeiro/etiologia Transplante de Células-Tronco Hematopoéticas/mortalidade Seres Humanos Leucemia/mortalidade Leucemia/terapia Leucemia Aguda Bifenotípica/diagnóstico Leucemia Aguda Bifenotípica/mortalidade Leucemia Aguda Bifenotípica/terapia Transfusão de Linfócitos Masculino Meia-Idade Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia Estudos Retrospectivos Medição de Risco Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE [Em] Mês de entrada: 1710 [Cu] Atualização por classe: 171003 [Lr] Data última revisão: 171003 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170521 [St] Status: MEDLINE

3 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28436985 [Au] Autor: Vu LP; Prieto C; Amin EM; Chhangawala S; Krivtsov A; Calvo-Vidal MN; Chou T; Chow A; Minuesa G; Park SM; Barlowe TS; Taggart J; Tivnan P; Deering RP; Chu LP; Kwon JA; Meydan C; Perales-Paton J; Arshi A; Gönen M; Famulare C; Patel M; Paietta E; Tallman MS; Lu Y; Glass J; Garret-Bakelman FE; Melnick A; Levine R; Al-Shahrour F; Järås M; Hacohen N; Hwang A; Garippa R; Lengner CJ; Armstrong SA; Cerchietti L; Cowley GS; Root D; Doench J; Leslie C; Ebert BL; Kharas MG [Ad] Endereço: Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, and Center for Experimental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [Ti] Título: Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. [So] Source: Nat Genet;49(6):866-875, 2017 Jun. [Is] ISSN: 1546-1718 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: The identity of the RNA-binding proteins (RBPs) that govern cancer stem cells remains poorly characterized. The MSI2 RBP is a central regulator of translation of cancer stem cell programs. Through proteomic analysis of the MSI2-interacting RBP network and functional shRNA screening, we identified 24 genes required for in vivo leukemia. Syncrip was the most differentially required gene between normal and myeloid leukemia cells. SYNCRIP depletion increased apoptosis and differentiation while delaying leukemogenesis. Gene expression profiling of SYNCRIP-depleted cells demonstrated a loss of the MLL and HOXA9 leukemia stem cell program. SYNCRIP and MSI2 interact indirectly though shared mRNA targets. SYNCRIP maintains HOXA9 translation, and MSI2 or HOXA9 overexpression rescued the effects of SYNCRIP depletion. Altogether, our data identify SYNCRIP as a new RBP that controls the myeloid leukemia stem cell program. We propose that targeting these RBP complexes might provide a novel therapeutic strategy in leukemia. [Mh] Termos MeSH primário: Regulação Leucêmica da Expressão Gênica Ribonucleoproteínas Nucleares Heterogêneas/genética Leucemia Mieloide/genética Proteínas de Ligação a RNA/metabolismo [Mh] Termos MeSH secundário: Animais Sobrevivência Celular Feminino Hematopoese/genética Ribonucleoproteínas Nucleares Heterogêneas/metabolismo Proteínas de Homeodomínio/genética Seres Humanos Leucemia Aguda Bifenotípica/genética Leucemia Aguda Bifenotípica/patologia Leucemia Mieloide/patologia Camundongos Endogâmicos C57BL Camundongos Knockout Células Progenitoras Mieloides/metabolismo Células Progenitoras Mieloides/patologia RNA Interferente Pequeno Proteínas de Ligação a RNA/genética Ensaios Antitumorais Modelo de Xenoenxerto [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Heterogeneous-Nuclear Ribonucleoproteins); 0 (Homeodomain Proteins); 0 (MSI2 protein, human); 0 (RNA, Small Interfering); 0 (RNA-Binding Proteins); 0 (SYNCRIP protein, human); 0 (Syncrip protein, mouse); 0 (homeobox protein HOXA9) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 171024 [Lr] Data última revisão: 171024 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170425 [St] Status: MEDLINE [do] DOI: 10.1038/ng.3854

4 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28195090 [Au] Autor: Pawar RN; Banerjee S; Bramha S; Krishnan S; Bhattacharya A; Saha V; Chakrapani A; Bhave S; Chandy M; Nair R; Parihar M; Arora N; Mishra DK [Ad] Endereço: Department of Laboratory Haematology and Molecular Genetics, Tata Medical Centre, Kolkata, West Bengal, India. [Ti] Título: Mixed-phenotypic acute leukemia series from tertiary care center. [So] Source: Indian J Pathol Microbiol;60(1):43-49, 2017 Jan-Mar. [Is] ISSN: 0974-5130 [Cp] País de publicação: India [La] Idioma: eng [Ab] Resumo: INTRODUCTION: Mixed-phenotype acute leukemias (MPALs) are a heterogeneous group of rare leukemias constituting approximately 2%-5% of all leukemias, in which assigning a single lineage of origin is not possible. They are diagnosed by either the presence of antigens of more than one lineage or by the presence of dual population of blasts belonging to two or more lineages. We highlight the clinicopathological, immunophenotype, and genetic data of a cohort (n = 14) of patients diagnosed and treated at our center. MATERIALS AND METHODS: We retrospectively analyzed consecutive cases of MPAL diagnosed in our flow cytometry laboratory from May 2012 to August 2015. These cases were diagnosed based on immunophenotyping of peripheral blood/bone marrow aspirates and morphology/genetics wherever available as per the World Health Organization (WHO) 2008 guideline. RESULTS: Among 628 consecutive acute leukemia (AL) cases diagnosed and evaluated during this period, we identified 14 (2.2%) patients with MPAL fulfilling WHO 2008/EGIL criteria for immunological characterizing of AL criteria. Majority of these were males (n = 8, male:female ratio 1.3:1) and adults (n = 11, 78.5%). The median age of this cohort was 41 years (range 2-80). These cases were further classified as: B/myeloid (n = 9), T/myeloid (n = 4), and B/T MPAL (n = 1). Cytogenetics was available in 12 out of 14 cases, out of which, three cases had normal karyotype, three with t(9;22)(q34;q11), and two cases with complex karyotype. We also came across a rare case of B + T lymphoid MPAL who had mixed-lineage leukemia gene t(v; 11q23) rearrangement. CONCLUSION: MPAL is a complex entity with heterogeneous clinical, immunophenotypic, cytogenetic, and molecular features. Multiparametric flowcytometry by using comprehensive antibody panels is a valuable tool for diagnosis. Subsequent cytogenetic and molecular analysis for further prognostic stratification and treatment modalities are important. [Mh] Termos MeSH primário: Leucemia Aguda Bifenotípica/diagnóstico Leucemia Aguda Bifenotípica/patologia [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Idoso de 80 Anos ou mais Células Sanguíneas Medula Óssea/patologia Criança Pré-Escolar Feminino Citometria de Fluxo Seres Humanos Imunofenotipagem Masculino Meia-Idade Estudos Retrospectivos Centros de Atenção Terciária Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE [Em] Mês de entrada: 1703 [Cu] Atualização por classe: 170313 [Lr] Data última revisão: 170313 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170215 [St] Status: MEDLINE [do] DOI: 10.4103/0377-4929.200057

5 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28099272 [Au] Autor: Wolach O; Stone RM [Ad] Endereço: aLeukemia Service, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel bDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [Ti] Título: Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. [So] Source: Curr Opin Hematol;24(2):139-145, 2017 Mar. [Is] ISSN: 1531-7048 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: PURPOSE OF REVIEW: Mixed-phenotype acute leukemia (MPAL) is a rare disease that poses many diagnostic and therapeutic challenges. Patients with MPAL are considered to have poor outcomes. The difficulties in classifying this leukemia, the lack of prospectively collected data concerning therapeutic outcomes, and rare incidence result in much uncertainty as to the best approach for patients with MPAL. RECENT FINDINGS: Recent studies demonstrated that most MPALs are associated with cytogenetic abnormalities; genetic sequencing studies disclose a high frequency of somatic mutations in genes encoding epigenetic regulators, tumor suppressors, and transcription factors. The limited available data suggest that higher remission rates are achieved with acute lymphoblastic leukemia-like induction regimens compared with acute myeloid leukemia-type approaches. Allogeneic transplantation in first remission may be associated with improved survival compared with consolidation chemotherapy. SUMMARY: Advances in understanding the genetic landscape of MPAL may allow a more biologically driven classification of this heterogeneous group of leukemias in the future that will lead to optimized therapies for individual patients. Most data that inform therapy are based on retrospective, uncontrolled studies; prospective trials that incorporate targeted approaches based on genetics and immunophenotype are needed. [Mh] Termos MeSH primário: Leucemia Aguda Bifenotípica/diagnóstico Leucemia Aguda Bifenotípica/terapia [Mh] Termos MeSH secundário: Biomarcadores Tumorais Terapia Combinada Variação Genética Transplante de Células-Tronco Hematopoéticas Seres Humanos Imunofenotipagem Leucemia Aguda Bifenotípica/genética Leucemia Aguda Bifenotípica/metabolismo Indução de Remissão Transplante Homólogo Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Biomarkers, Tumor) [Em] Mês de entrada: 1710 [Cu] Atualização por classe: 171024 [Lr] Data última revisão: 171024 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170119 [St] Status: MEDLINE [do] DOI: 10.1097/MOH.0000000000000322

6 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28068328 [Au] Autor: Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D [Ad] Endereço: Molecular Hematology, Institution for Laboratory Medicine, Lund University, Lund, Sweden. [Ti] Título: MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment. [So] Source: Oncogene;36(22):3207-3212, 2017 Jun 01. [Is] ISSN: 1476-5594 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: Translocations involving the mixed lineage leukemia-1 are recurrent events in acute leukemia and associate with lymphoid (ALL), myeloid (AML) or mixed lineage (MLL) subtypes. Despite an association with ALL in humans, murine MLL fusion models are persistently restricted to AML. We here explored this issue using an inducible mixed lineage leukemia-eleven nineteen leukemia (MLL-ENL) mouse model. Although multiple progenitor cell types with myeloid potential are potent AML leukemia-initiating cells, also the earliest lymphoid progenitors were capable of initiating AML. This ability to evoke a latent myeloid potential in the earliest lymphoid progenitors was lost upon further lymphoid commitment. At the same time, more downstream/committed lymphoid precursors also failed to initiate lymphoid leukemia. Co-expression of MLL-ENL with a constitutively active RAS allele, the most common co-mutation in MLL fusion leukemias, could influence on both disease latency and lineage assignment of developing leukemia in what appears to be a mutation-order-dependent manner. Finally, CEBPB-mediated transdifferentation of committed and otherwise leukemia-incompetent B-cell progenitors imbued these cells with leukemic competence for AML. Therefore, apart from providing detailed insight into the differential responsiveness of candidate target cells to a first-hit MLL fusion event, our data warrants caution to therapeutic approaches based on the concept of transdifferentiation. [Mh] Termos MeSH primário: Proteínas de Ligação a DNA/genética Histona-Lisina N-Metiltransferase/genética Leucemia Aguda Bifenotípica/genética Proteína de Leucina Linfoide-Mieloide/genética Proteínas de Fusão Oncogênicas/genética Fatores de Transcrição/genética [Mh] Termos MeSH secundário: Animais Transformação Celular Neoplásica Proteínas de Ligação a DNA/metabolismo Modelos Animais de Doenças Histona-Lisina N-Metiltransferase/metabolismo Leucemia Aguda Bifenotípica/metabolismo Leucemia Aguda Bifenotípica/patologia Camundongos Proteína de Leucina Linfoide-Mieloide/metabolismo Proteínas de Fusão Oncogênicas/metabolismo Fatores de Transcrição/metabolismo Translocação Genética [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (DNA-Binding Proteins); 0 (Mllt1 protein, mouse); 0 (Oncogene Proteins, Fusion); 0 (Transcription Factors); 149025-06-9 (Myeloid-Lymphoid Leukemia Protein); EC 2.1.1.43 (Histone-Lysine N-Methyltransferase); EC 2.1.1.43 (Mll protein, mouse) [Em] Mês de entrada: 1709 [Cu] Atualização por classe: 170926 [Lr] Data última revisão: 170926 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170110 [St] Status: MEDLINE [do] DOI: 10.1038/onc.2016.470

7 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28065413 [Au] Autor: Liang K; Volk AG; Haug JS; Marshall SA; Woodfin AR; Bartom ET; Gilmore JM; Florens L; Washburn MP; Sullivan KD; Espinosa JM; Cannova J; Zhang J; Smith ER; Crispino JD; Shilatifard A [Ad] Endereço: Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, 320 E. Superior St., Chicago, IL 60611, USA; Stowers Institute for Medical Research, 1000 E. 50th St., Kansas City, MO 64110, USA. [Ti] Título: Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. [So] Source: Cell;168(1-2):59-72.e13, 2017 Jan 12. [Is] ISSN: 1097-4172 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Chromosomal translocations of the mixed-lineage leukemia (MLL) gene with various partner genes result in aggressive leukemia with dismal outcomes. Despite similar expression at the mRNA level from the wild-type and chimeric MLL alleles, the chimeric protein is more stable. We report that UBE2O functions in regulating the stability of wild-type MLL in response to interleukin-1 signaling. Targeting wild-type MLL degradation impedes MLL leukemia cell proliferation, and it downregulates a specific group of target genes of the MLL chimeras and their oncogenic cofactor, the super elongation complex. Pharmacologically inhibiting this pathway substantially delays progression, and it improves survival of murine leukemia through stabilizing wild-type MLL protein, which displaces the MLL chimera from some of its target genes and, therefore, relieves the cellular oncogenic addiction to MLL chimeras. Stabilization of MLL provides us with a paradigm in the development of therapies for aggressive MLL leukemia and perhaps for other cancers caused by translocations. [Mh] Termos MeSH primário: Leucemia Aguda Bifenotípica/tratamento farmacológico Leucemia Aguda Bifenotípica/metabolismo Proteólise/efeitos dos fármacos [Mh] Termos MeSH secundário: Animais Modelos Animais de Doenças Histona-Lisina N-Metiltransferase/metabolismo Seres Humanos Interleucina-1/metabolismo Quinases Associadas a Receptores de Interleucina-1/antagonistas & inibidores Quinases Associadas a Receptores de Interleucina-1/metabolismo Camundongos Camundongos Endogâmicos C57BL Proteína de Leucina Linfoide-Mieloide/metabolismo Enzimas de Conjugação de Ubiquitina [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Interleukin-1); 149025-06-9 (Myeloid-Lymphoid Leukemia Protein); EC 2.1.1.43 (Histone-Lysine N-Methyltransferase); EC 2.1.1.43 (Mll protein, mouse); EC 2.3.2.23 (Ubiquitin-Conjugating Enzymes); EC 2.3.2.24 (UBE2O protein, human); EC 2.7.11.1 (Interleukin-1 Receptor-Associated Kinases) [Em] Mês de entrada: 1705 [Cu] Atualização por classe: 171028 [Lr] Data última revisão: 171028 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170110 [St] Status: MEDLINE

8 / 263

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 27696204 [Au] Autor: Vogt N; Heß K; Bialek R; Buerke B; Brüggemann M; Topp MS; Groth C; Berdel WE; Lenz G; Stelljes M [Ad] Endereço: Department of Medicine A/Hematology and Oncology, University of Muenster, Albert-Schweitzer-Campus 1, D-48149, Muenster, Germany. [Ti] Título: Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. [So] Source: Ann Hematol;96(1):151-153, 2017 Jan. [Is] ISSN: 1432-0584 [Cp] País de publicação: Germany [La] Idioma: eng [Mh] Termos MeSH primário: Anticorpos Biespecíficos/efeitos adversos Antineoplásicos/efeitos adversos Encefalopatias/induzido quimicamente Epilepsia/induzido quimicamente Leucemia Aguda Bifenotípica/tratamento farmacológico Mucormicose/induzido quimicamente [Mh] Termos MeSH secundário: Encefalopatias/complicações Encefalopatias/diagnóstico por imagem Epilepsia/complicações Epilepsia/diagnóstico por imagem Evolução Fatal Feminino Seres Humanos Leucemia Aguda Bifenotípica/complicações Leucemia Aguda Bifenotípica/diagnóstico por imagem Mucormicose/complicações Mucormicose/diagnóstico por imagem Adulto Jovem [Pt] Tipo de publicação: CASE REPORTS; LETTER [Nm] Nome de substância: 0 (Antibodies, Bispecific); 0 (Antineoplastic Agents); 4FR53SIF3A (blinatumomab) [Em] Mês de entrada: 1702 [Cu] Atualização por classe: 170201 [Lr] Data última revisão: 170201 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 161004 [St] Status: MEDLINE [do] DOI: 10.1007/s00277-016-2837-1

9 / 263

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 28134942 [Au] Autor: Rodríguez-Rodríguez S; Pomerantz A; Demichelis-Gómez R; Barrera-Lumbreras G; Barrales-Benítez OV; Lopez-Karpovitch X; Aguayo Á [Ad] Endereço: Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. [Ti] Título: Impact of Aberrant Antigens in the Outcome of Patients with Acute Leukemia at a Referral Institution in Mexico City. [So] Source: Rev Invest Clin;68(6):305-313, 2016 Nov-Dec. [Is] ISSN: 0034-8376 [Cp] País de publicação: Mexico [La] Idioma: eng [Ab] Resumo: BACKGROUND: Patients with acute leukemia can express aberrant markers, defined as antigens that are normally restricted to a different lineage. The reported significance and frequency of these markers is inconclusive. We assessed the frequency and impact of aberrant markers in patients with acute leukemia in a referral institution in Mexico City. METHODS: We included 433 patients, diagnosed and treated between 2005 and 2015 in our institution. RESULTS: Aberrant markers were expressed in 128 patients (29.6%); CD13 and CD33 were the most frequent aberrant markers in patients with acute lymphoblastic leukemia, while CD7 and CD19 were the most frequent in patients with acute myeloid leukemia. In the univariate analysis, the group with aberrant markers had a lower disease-free survival when compared with the aberrant-free group (8 vs. 13 months) (p = 0.03). Aberrant expression of CD10, CD20, and CD33 correlated with a worse outcome in a statistically significant manner. In the multivariate analysis, male gender, lymphoid lineage, secondary leukemia, high risk at diagnosis, and the presence of aberrant markers had a significantly negative impact on disease-free survival. CONCLUSION: The use of more aggressive treatment strategies could be considered in patients with acute leukemia and an aberrant expression of CD10, CD20, and CD33. [Mh] Termos MeSH primário: Antígenos CD/sangue Antígenos de Neoplasias/sangue Leucemia Mieloide Aguda/sangue Leucemia-Linfoma Linfoblástico de Células Precursoras/sangue [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Idoso de 80 Anos ou mais Biomarcadores Tumorais/sangue Intervalo Livre de Doença Feminino Seguimentos Seres Humanos Leucemia Aguda Bifenotípica/sangue Masculino México Meia-Idade Análise Multivariada Estudos Retrospectivos Fatores de Risco Adulto Jovem [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antigens, CD); 0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor) [Em] Mês de entrada: 1707 [Cu] Atualização por classe: 170817 [Lr] Data última revisão: 170817 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170131 [St] Status: MEDLINE

10 / 263

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 27607436 [Au] Autor: Yamamoto K; Kawamoto S; Mizutani Y; Yakushijin K; Yamashita T; Nakamachi Y; Kawano S; Hayashi Y; Matsuoka H; Minami H [Ad] Endereço: Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. [Ti] Título: Mixed Phenotype Acute Leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and Other Chromosome Abnormalities. [So] Source: Cytogenet Genome Res;149(3):165-170, 2016. [Is] ISSN: 1424-859X [Cp] País de publicação: Switzerland [La] Idioma: eng [Ab] Resumo: The t(12;17)(p13;q11∼21) translocation is a very rare but recurrent cytogenetic aberration observed predominantly in early pre-B acute lymphoblastic leukemia (ALL) with CD19+CD10-CD33+ phenotype. This translocation was shown to form a fusion gene between TAF15 at 17q12 and ZNF384 at 12p13. On the other hand, der(1;18)(q10;q10) has been detected as a rare unbalanced whole-arm translocation leading to trisomy 1q in myeloid malignancies. We describe here the first case of mixed phenotype acute leukemia (MPAL) with a t(12;17)(p13;q21)/TAF15-ZNF384, which also had der(1;18)(q10;q10) as an additional abnormality. A 74-year-old woman was diagnosed with MPAL, B/myeloid, because bone marrow blasts were positive for myeloperoxidase, CD19, and CD22. Chromosome analysis showed 46,XX, +1,der(1;18)(q10;q10),t(2;16)(q13;q13),t(12;17)(p13;q21). Expression of the TAF15-ZNF384 fusion transcript was confirmed: TAF15 exon 6 was fused in-frame to ZNF384 exon 3. This type of fusion gene has been reported in 1 acute myeloid leukemia case and 3 ALL cases. Thus, at present, it is difficult to find a specific association between the structure of the TAF15-ZNF384 fusion gene and the leukemia phenotype. The TAF15-ZNF384 fusion may occur in early common progenitor cells that could differentiate into both the myeloid and lymphoid lineages. Furthermore, der(1;18)(q10;q10) might play some role in the appearance of an additional myeloid phenotype. [Mh] Termos MeSH primário: Aberrações Cromossômicas Cromossomos Humanos Par 12/genética Cromossomos Humanos Par 17/genética Leucemia Aguda Bifenotípica/genética Fatores Associados à Proteína de Ligação a TATA/genética Transativadores/genética Translocação Genética/genética [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Sequência de Bases Criança Pré-Escolar Bandeamento Cromossômico Éxons/genética Feminino Seres Humanos Cariótipo Masculino Proteínas de Fusão Oncogênicas/genética Fenótipo Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética Reação em Cadeia da Polimerase Via Transcriptase Reversa Trissomia/genética Adulto Jovem [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Oncogene Proteins, Fusion); 0 (TAF15 protein, human); 0 (TATA-Binding Protein Associated Factors); 0 (Trans-Activators); 0 (ZNF384 protein, human) [Em] Mês de entrada: 1701 [Cu] Atualização por classe: 170116 [Lr] Data última revisão: 170116 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 160909 [St] Status: MEDLINE

---

página 1 de 27

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde